These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 22880124

  • 21. Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany.
    Schwarze-Zander C, Draenert R, Lehmann C, Stecher M, Boesecke C, Sammet S, Wasmuth JC, Seybold U, Gillor D, Wieland U, Kümmerle T, Strassburg CP, Mankertz A, Eis-Hübinger AM, Jäger G, Fätkenheuer G, Bogner JR, Rockstroh JK, Vehreschild JJ.
    Epidemiol Infect; 2017 Jan; 145(2):236-244. PubMed ID: 27780480
    [Abstract] [Full Text] [Related]

  • 22. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.
    Waaijenborg S, Hahné SJ, Mollema L, Smits GP, Berbers GA, van der Klis FR, de Melker HE, Wallinga J.
    J Infect Dis; 2013 Jul; 208(1):10-6. PubMed ID: 23661802
    [Abstract] [Full Text] [Related]

  • 23. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM.
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [Abstract] [Full Text] [Related]

  • 24. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination.
    Mahamud A, Masunu-Faleafaga Y, Walls L, Williams N, Garcia P, Teshale E, Williams R, Dulski T, Bellini WJ, Kutty PK.
    Vaccine; 2013 Aug 12; 31(36):3683-7. PubMed ID: 23770334
    [Abstract] [Full Text] [Related]

  • 25. Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium.
    Theeten H, Hutse V, Hens N, Yavuz Y, Hoppenbrouwers K, Beutels P, Vranckx R, Van Damme P.
    Epidemiol Infect; 2011 Apr 12; 139(4):494-504. PubMed ID: 20587123
    [Abstract] [Full Text] [Related]

  • 26. Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titres in a German population-based cross-sectional study in children and adolescents (KiGGS).
    Poethko-Müller C, Mankertz A.
    Vaccine; 2011 Oct 19; 29(45):7949-59. PubMed ID: 21872633
    [Abstract] [Full Text] [Related]

  • 27. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R, Praparattanapan J, Nuket K, Kotarathitithum W, Supparatpinyo K.
    BMC Infect Dis; 2016 Apr 30; 16():190. PubMed ID: 27138005
    [Abstract] [Full Text] [Related]

  • 28. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.
    Leuridan E, Maertens K, Wautier M, Hutse V, Theeten H.
    Eur J Pediatr; 2015 Jul 30; 174(7):925-32. PubMed ID: 25579232
    [Abstract] [Full Text] [Related]

  • 29. Use of a microquantity enzyme immunoassay in a large-scale study of measles, mumps and rubella immunity in Italy.
    Condorelli F, Stivala A, Gallo R, Marino A, Battaglini CM, Messina A, Russo G, Castro A, Scalia G.
    Eur J Clin Microbiol Infect Dis; 1998 Jan 30; 17(1):49-52. PubMed ID: 9512184
    [Abstract] [Full Text] [Related]

  • 30. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martínez D, Trumbo SP, Fernández de Castro J.
    Vaccine; 2017 May 25; 35(23):3116-3122. PubMed ID: 28457672
    [Abstract] [Full Text] [Related]

  • 31. Missed Opportunities for Measles, Mumps, and Rubella (MMR) Immunization in Mesoamerica: Potential Impact on Coverage and Days at Risk.
    Mokdad AH, Gagnier MC, Colson KE, Dansereau E, Zúñiga-Brenes P, Ríos-Zertuche D, Haakenstad A, Johanns CK, Palmisano EB, Hernandez B, Iriarte E.
    PLoS One; 2015 May 25; 10(10):e0139680. PubMed ID: 26506563
    [Abstract] [Full Text] [Related]

  • 32. Seroprevalences of antibodies against pertussis, diphtheria, tetanus, measles, mumps and rubella: A cross-sectional study in children following vaccination procedure in Guangzhou, China.
    Li YT, Luo XQ, Zhong XB, Cai LM, Zhu LP, Chen XQ, Wang KC, Chen ZG.
    Vaccine; 2020 May 13; 38(23):3960-3967. PubMed ID: 32321685
    [Abstract] [Full Text] [Related]

  • 33. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S, Feyssaguet M, Povey M, Di Paolo E.
    Vaccine; 2019 Aug 23; 37(36):5323-5331. PubMed ID: 31345639
    [Abstract] [Full Text] [Related]

  • 34. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P.
    Eur J Pediatr; 2012 Mar 23; 171(3):463-70. PubMed ID: 21935584
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C, Pachón I, de Ory F.
    Eur J Epidemiol; 2003 Mar 23; 18(1):71-9. PubMed ID: 12705626
    [Abstract] [Full Text] [Related]

  • 36. Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants.
    Malshe N, Palkar S, Kulkarni R, Lalwani S, Mishra AC, Arankalle V.
    Vaccine; 2019 Mar 07; 37(11):1443-1448. PubMed ID: 30765170
    [Abstract] [Full Text] [Related]

  • 37. Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.
    Nogareda F, Gunregjav N, Sarankhuu A, Munkhbat E, Ichinnorov E, Nymadawa P, Wannemuehler K, Mulders MN, Hagan J, Patel MK.
    Vaccine; 2020 May 27; 38(26):4200-4208. PubMed ID: 32381479
    [Abstract] [Full Text] [Related]

  • 38. High seroprevalence of varicella, measles, mumps, rubella and pertussis antibodies in first-grade medical students.
    Socan M, Berginc N.
    Wien Klin Wochenschr; 2008 May 27; 120(13-14):422-6. PubMed ID: 18726668
    [Abstract] [Full Text] [Related]

  • 39. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
    Ödemiş Í, Köse Ş, Akbulut Í, Albayrak H.
    Rev Esp Quimioter; 2019 Dec 27; 32(6):525-531. PubMed ID: 31642641
    [Abstract] [Full Text] [Related]

  • 40. Utility of serological screening for measles, mumps and rubella in immunocompromised patients.
    Sticchi L, Astengo M, Iavarone IG, Icardi G.
    Hum Vaccin Immunother; 2019 Dec 27; 15(12):2854-2855. PubMed ID: 31442102
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.